JP2002502882A5 - - Google Patents

Download PDF

Info

Publication number
JP2002502882A5
JP2002502882A5 JP2000531187A JP2000531187A JP2002502882A5 JP 2002502882 A5 JP2002502882 A5 JP 2002502882A5 JP 2000531187 A JP2000531187 A JP 2000531187A JP 2000531187 A JP2000531187 A JP 2000531187A JP 2002502882 A5 JP2002502882 A5 JP 2002502882A5
Authority
JP
Japan
Prior art keywords
interleukin
suspension
mineral
carrier molecule
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000531187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/002847 external-priority patent/WO1999040936A2/en
Publication of JP2002502882A publication Critical patent/JP2002502882A/ja
Publication of JP2002502882A5 publication Critical patent/JP2002502882A5/ja
Pending legal-status Critical Current

Links

JP2000531187A 1998-02-12 1999-02-10 インターロイキン−12とともに処方された肺炎球菌および髄膜炎菌のワクチン Pending JP2002502882A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7452898P 1998-02-12 1998-02-12
US60/074,528 1998-02-12
PCT/US1999/002847 WO1999040936A2 (en) 1998-02-12 1999-02-10 Pneumococcal and meningococcal vaccines formulated with interleukin-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009193167A Division JP2010006827A (ja) 1998-02-12 2009-08-24 インターロイキン−12とともに処方された髄膜炎菌のワクチン
JP2010144063A Division JP2010265279A (ja) 1998-02-12 2010-06-24 インターロイキン−12とともに処方された肺炎球菌および髄膜炎菌のワクチン

Publications (2)

Publication Number Publication Date
JP2002502882A JP2002502882A (ja) 2002-01-29
JP2002502882A5 true JP2002502882A5 (https=) 2006-03-02

Family

ID=22120049

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000531187A Pending JP2002502882A (ja) 1998-02-12 1999-02-10 インターロイキン−12とともに処方された肺炎球菌および髄膜炎菌のワクチン
JP2009193167A Pending JP2010006827A (ja) 1998-02-12 2009-08-24 インターロイキン−12とともに処方された髄膜炎菌のワクチン
JP2010144063A Pending JP2010265279A (ja) 1998-02-12 2010-06-24 インターロイキン−12とともに処方された肺炎球菌および髄膜炎菌のワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009193167A Pending JP2010006827A (ja) 1998-02-12 2009-08-24 インターロイキン−12とともに処方された髄膜炎菌のワクチン
JP2010144063A Pending JP2010265279A (ja) 1998-02-12 2010-06-24 インターロイキン−12とともに処方された肺炎球菌および髄膜炎菌のワクチン

Country Status (9)

Country Link
EP (1) EP1053015A2 (https=)
JP (3) JP2002502882A (https=)
KR (1) KR100585408B1 (https=)
CN (1) CN1200730C (https=)
AU (1) AU759391B2 (https=)
BR (1) BR9907884A (https=)
CA (1) CA2320223A1 (https=)
IL (2) IL137809A0 (https=)
WO (1) WO1999040936A2 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137809A0 (en) * 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
MXPA02000842A (es) 1999-07-22 2002-07-30 Procter & Gamble Conjugados de proteasa que tienen sitios de corte protegidos estericamente.
CN1373802A (zh) 1999-07-22 2002-10-09 宝洁公司 在特定表位区域具有氨基酸缺失和取代的枯草杆菌蛋白酶变体
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
BR0012660A (pt) 1999-07-22 2002-04-09 Procter & Gamble Variante de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
EP3311836A1 (en) * 2005-04-08 2018-04-25 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2006123164A2 (en) * 2005-05-19 2006-11-23 The Edward Jenner Institute For Vaccine Research Lps-binding and bactericidal cytokines and interferons
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
ES2687129T3 (es) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2755994A2 (en) 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2727476C2 (ru) 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
RU2014151567A (ru) 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
TR201808684T4 (tr) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN114544913B (zh) * 2022-02-23 2024-04-09 沈阳建筑大学 一种土壤调查加密采样布点优化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
JPH10502366A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
DK0784486T3 (da) * 1994-10-05 2006-08-14 Univ Vanderbilt Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
US5866134A (en) * 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
US6438586B1 (en) * 1996-09-30 2002-08-20 Emc Corporation File transfer utility which employs an intermediate data storage system
IL137809A0 (en) * 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) * 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens

Similar Documents

Publication Publication Date Title
JP2002502882A5 (https=)
CA2366314A1 (en) Protein d from haemophilus influenzae as a carrier protein in combination vaccines
WO2002000249A3 (en) Multivalent vaccine composition
JP2004501873A5 (https=)
JP2005526847A5 (https=)
JP2007516219A5 (https=)
JP2005508849A5 (https=)
BR112019026192B1 (pt) Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas
RU2012116119A (ru) Множественная вакцинация, включающая менингококки серогруппы с
JP2005504718A5 (https=)
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
WO2002058737A3 (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
SG168517A1 (en) Pneumococcal polysaccharide conjugate vaccine
MX2009006548A (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
JP2009525260A5 (https=)
CA2392880A1 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c
JPH04230634A (ja) 複合ワクチンのキヤリヤー分子としての、百日咳菌の繊維状赤血球凝集素
TW200719911A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
AR040922A1 (es) Composicion inmunogenica multivalente, uso de la misma para la fabricacion de un medicamento y procedimiento para preparar dicha composicion inmunogenica multivalente
JP2011042693A5 (https=)
JP2006528936A5 (https=)
WO2005000345A3 (en) Immunization method against neisseria meningitidis serogroups a and c
Makela Conjugate vaccines-a breakthrough in vaccine development
JP2003510292A5 (https=)
Moingeon Challenges and Opportunities in the Development of New Conjugate Vaccines against Infectious Diseases